OUR EXPERT NETWORK

• Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune Reset

  In this Q&A, Michael Lam, Ph.D., explores how circular RNA and targeted delivery extend transient CAR expression to enable deep B-cell depletion and controllable immune reset.

• Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics

  Designing repeat-dose RNA means engineering around immune recognition — optimizing payloads, purity, and delivery early to sustain efficacy, tolerability, and durability across multiple administrations.

• Bridging The Manufacturing Chemistries Between Drug Research And Development For Morpholino Oligos

  Standardizing Morpholino chemistry could streamline development and FDA pathways, improving consistency, scalability, and delivery performance across antisense therapeutics.

• From Supporting Component to Strategic Driver: The Evolving Role of gRNA in CRISPR Therapeutics

  Guide RNA is evolving from a simple targeting reagent into a complex, engineered molecule shaped by expanding CRISPR modalities, increasing length and modification demands, and tighter integration with manufacturability, analytical control, and regulatory expectations.

• A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis

  Co-tethered transcription boosts mRNA yield and purity by organizing transcription machinery, reducing dsRNA impurities, and streamlining production for scalable RNA therapeutics.